Tight junction protein CLDN18.2 is expressed in normal gastric mucosal epithelial cells and also in solid tumors such as gastric,colon,and pancreatic cancers,which is a potential ther-apeutic target for digestive system tumors.Various targeted therapies against CLDN18.2 have been designed,including monoclonal antibody,chimeric antigen receptor T-cell therapy(CAR-T),bis-pecific antibody,and antibody-drug conjugate.Currently,clinical trials of several CLDN18.2-tar-geting drugs are ongoing,among which trials of Zolbetuximab have been advanced most.This paper provides a comprehensive review of research progress on CLDN18.2 and its applications in advanced gastric cancer.
NETL
NSTL
万方数据
